Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
05 2019
Historique:
received: 14 01 2019
revised: 26 02 2019
accepted: 26 02 2019
pubmed: 5 3 2019
medline: 16 1 2020
entrez: 5 3 2019
Statut: ppublish

Résumé

The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlie the diversity of growth patterns of this malignancy remain a clinical concern. Tumours of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumour heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behaviour. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies.

Identifiants

pubmed: 30829432
doi: 10.1111/liv.14085
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-42

Subventions

Organisme : Pancreatic Cancer UK
ID : RIF2014_01_BRACONI
Pays : United Kingdom

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Chiara Braconi (C)

Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Trust, Surrey and London, UK.

Stephanie Roessler (S)

Institute of Pathology, University Hospital Heidelberg and Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Beata Kruk (B)

Department of General, Transplant and Liver Surgery, Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.

Frank Lammert (F)

Department of Medicine II, Saarland University Medical Center, Homburg, Germany.

Marcin Krawczyk (M)

Department of General, Transplant and Liver Surgery, Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Department of Medicine II, Saarland University Medical Center, Homburg, Germany.

Jesper B Andersen (JB)

Department of Health and Medical Sciences, Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen N, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH